Merger • Life Science

Mereo BioPharma Group Acquires OncoMed Pharmaceuticals

On December 5, 2018, Mereo BioPharma Group acquired life science company OncoMed Pharmaceuticals

Acquisition Context

This is Mereo BioPharma Group’s 1st transaction in the Life Science sector.
This is Mereo BioPharma Group’s 1st transaction in the United States.
This is Mereo BioPharma Group’s 1st transaction in California.

Explore All 191 Merger Life Science Deals - Search the Database Free

M&A Deal Summary
Date	December 5, 2018
Target	OncoMed Pharmaceuticals
Sector	Life Science
Buyer(s)	Mereo BioPharma Group
Deal Type	Merger
Advisor(s)	Leerink Partners (Financial)

Target Company

OncoMed Pharmaceuticals

Redwood City, California, United States

OncoMed Pharmaceuticals, Inc. is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is based in Redwood City, California.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Mereo BioPharma Group

London, United Kingdom

Category	Company
Founded	2015
Sector	Life Science
Employees	36
Revenue	10M GBP (2023)

DESCRIPTION

Mereo BioPharma Group is a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Mereo BioPharma Group was founded in 2015 and is based in London, England.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Merger	1 of 1
State: California	1 of 1
Country: United States	1 of 1
Year: 2018	1 of 1

Explore Related M&A Activity

Life Science M&A - Merger M&A Deals - California M&A - United States M&A - 2018 M&A